Novartis launches interactive Retina App

Article

Novartis has launched a fully interactive Facebook app, ?Retina App,? which simulates retinal disease by illustrating the user?s journey with a highly realistic view of the possible impact of vision loss on their daily lives.

Basel, Switzerland-To raise awareness of retinal disease, Novartis has launched a fully interactive Facebook app, “Retina App” on World Sight Day October 10, 2013. The app, part of the “Set Your Sights” campaign, simulates retinal disease by illustrating the user’s journey with a highly realistic view of the possible impact of vision loss on their daily lives.

The app is geared to encourage patients with retinal diseases, such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization secondary to pathologic myopia, to engage with vision loss and experience what it means to live with a sight-diminishing condition. Users of the app will be presented with a fully tailored, through-the-lens view of their own photos and friends video experience that is a highly realistic view of what their life with retinal disease could be like.

The “Set Your Sights” campaign was mounted in response to the “2020 Vision Report” from the World Health Organization that concluded that nearly 80% of global blindness is preventable if managed correctly.

“As the global leader in the field of retinal disease, Novartis is proud to support World Sight Day by creating further dialogue among people living with low-vision conditions and the wider community, generating an environment of understanding and tolerance,” said David Epstein, head of the pharmaceuticals division, Novartis Pharma AG. “This is an important initiative in the pharmaceutical environment, reflecting our focus to always put the patient first.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.